Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Results of phase II FROST study of lefradafiban presented at ACC

March 11, 1999

Astra presents results of first human trial of AR-C69931MX at ACC meeting

March 11, 1999

Cor Therapeutics presents cromafiban, the first orally active once-daily gpIIb/IIIa antagonist

March 11, 1999

ACC highlights: ASSENT 2 study supports improved efficacy of TNK-tPA over t-PA

March 10, 1999

Fragmin found to reduce heart attack and death at 45 days

March 10, 1999

Subanalyses of abciximab trial results presented at ACC meeting

March 10, 1999

Yamanouchi describes novel anticoagulants

March 10, 1999

Hyseq conducts preclinical testing on novel anticoagulant products

March 10, 1999

Corvas presents phase I trial results of novel injectable anticoagulant at ACC meeting

March 9, 1999

Novel hemostatic cofactors available for licensing from OMRF

March 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026